Related Experiment Video
Updated: Mar 28, 2026
10:28
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.7K
Podocalyxin as a Prognostic Marker in Gastric Cancer.
Alli Laitinen1,2, Camilla Böckelman1,2, Jaana Hagström2,3
1Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Plos One
|December 18, 2015
Summary
Podocalyxin-like 1 (PODXL) expression in gastric cancer, detected by a polyclonal antibody, is linked to a poorer prognosis. This finding highlights PODXL as a potential independent marker for gastric cancer survival outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein implicated in aggressive tumor phenotypes and poor prognosis across various cancers.
- Investigating PODXL expression in gastric cancer is crucial for understanding its role in disease progression.
Purpose of the Study:
- To evaluate PODXL expression in gastric adenocarcinoma using two distinct antibodies.
- To determine the association between PODXL expression and clinicopathologic variables, including patient survival.
Main Methods:
- Tumor-tissue microarrays and immunohistochemistry were employed on specimens from 337 gastric adenocarcinoma patients.
- Expression was assessed using a polyclonal antibody (HPA2110) and a monoclonal antibody (HES9).
Main Results:
- PODXL positivity rates varied between antibodies: 57.5% (polyclonal) and 76% (monoclonal).
- Polyclonal antibody expression correlated with intestinal type and reduced 5-year survival (p=0.001), remaining significant in multivariable analysis (HR=3.17).
- Both antibodies indicated associations with higher tumor proliferation (S-phase fraction and Ki-67).
Conclusions:
- PODXL expression, particularly by the polyclonal antibody HPA2110, serves as an independent prognostic marker in gastric cancer.
- This finding underscores the clinical relevance of PODXL in predicting patient survival in gastric adenocarcinoma.
